Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper

• Published in: ESMO open 2021-06, Vol.6 (3), p.100155-100155, Article 100155
• Main Authors: Gallo, M., Adinolfi, V., Morviducci, L., Acquati, S., Tuveri, E., Ferrari, P., Zatelli, M.C., Faggiano, A., Argentiero, A., Natalicchio, A., D'Oronzo, S., Danesi, R., Gori, S., Russo, A., Montagnani, M., Beretta, G.D., Di Bartolo, P., Silvestris, N., Giorgino, F.
• Format: Article
• Language: English
• Subjects: consensus; diabetes; early diagnosis; hyperglycaemia; pancreatic carcinoma; Review
• ISSN: 2059-7029; 2059-7029
• DOI: 10.1016/j.esmoop.2021.100155

Pancreatic cancer (PC) is a common cause of cancer-related death, due to difficulties in detecting early-stage disease, to its aggressive behaviour, and to poor response to systemic therapy. Therefore, developing strategies for early diagnosis of resectable PC is critical for improving survival. Diabetes mellitus is another major public health problem worldwide. Furthermore, diabetes can represent both a risk factor and a consequence of PC: nowadays, the relationship between these two diseases is considered a high priority for research. New-onset diabetes can be an early manifestation of PC, especially in a thin adult without a family history of diabetes. However, even if targeted screening for patients at higher risk of PC could be a promising approach, this is not recommended in asymptomatic adults with new-onset diabetes, due to the much higher incidence of hyperglycaemia than PC and to the lack of a safe and affordable PC screening test. Prompted by a well-established and productive multidisciplinary cooperation, the Italian Association of Medical Oncology (AIOM), the Italian Medical Diabetologists Association (AMD), the Italian Society of Endocrinology (SIE), and the Italian Society of Pharmacology (SIF) here review available evidence on the mechanisms linking diabetes and PC, addressing the feasibility of screening for early PC in patients with diabetes, and sharing a set of update statements with the aim of providing a state-of-the-art overview and a decision aid tool for daily clinical practice. •The incidence of PC is increasing and its prognosis is very poor; therefore, early detection is fundamental.•New-onset diabetes may be an early manifestation of PC, often disappearing after its resection.•Screening for PC is not currently recommended among people with new-onset diabetes, due to its high incidence.•Thin subjects >50 years old at the time of diabetes onset, with sudden weight loss and severe hyperglycaemia are at higher risk.•Currently some clinical models are promising for stratifying cancer risk in people with new-onset diabetes.